Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Cash & Equivalents (2018 - 2026)

Profound Medical has reported Cash & Equivalents over the past 8 years, most recently at $59.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 8.76% year-over-year to $59.7 million; the TTM value through Dec 2025 reached $59.7 million, up 8.76%, while the annual FY2025 figure was $59.7 million, 8.76% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $59.7 million at Profound Medical, up from $24.8 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $83.9 million in Q1 2021 and troughed at $24.8 million in Q3 2025.
  • A 5-year average of $51.2 million and a median of $46.5 million in 2022 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: surged 104228.6% in 2021 and later crashed 43.65% in 2023.
  • Year by year, Cash & Equivalents stood at $67.2 million in 2021, then tumbled by 30.73% to $46.5 million in 2022, then tumbled by 43.65% to $26.2 million in 2023, then soared by 109.48% to $54.9 million in 2024, then increased by 8.76% to $59.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for PROF at $59.7 million in Q4 2025, $24.8 million in Q3 2025, and $35.2 million in Q2 2025.